PhRMA is angered by Colombia’s move to cut prices for hepatitis C drugs

By Ed Silverman, StatNews

In the latest battle between drug makers and the Colombian government,  an industry trade group has asked the Colombian health minister to scrap a move that is designed to unilaterally lower the prices of hepatitis C drugs or, eventually, issue compulsory licenses.

The move comes after Colombian Health Minister Alejandro Gaviria last month issued a resolution to determine whether a so-called declaration of public interest should be pursued, a step needed to lower prices. In a letter sent to the minister on Monday, the Pharmaceutical Research and Manufacturers of America argued the resolution is “legally and procedurally deficient,” and should be revoked. Continue reading

Advertisements
Posted in Compulsory Licensing, Drug prices, Hepatitis C, Uncategorized | Leave a comment

Global Summit On IP And Access Discusses Impact Of TRIPS-Plus Measures On Public Health

Catherine Saez, Intellectual Property Watch | January 17, 2018

A network of civil society organisations chose the birthplace of the World Trade Organization, Marrakesh, to hold a global summit on intellectual property and access to medicines this week. Part of the summit focused on stringent IP measures in free trade agreements in particular with the European Union, introducing patent term extension and data exclusivity periods.

The Global Summit on Intellectual Property & Access to Medicines: Pathways to Access is taking place from 15-17 January in Marrakesh, Morocco. At the same time as the agreement to establish the World Trade Organization, the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) was adopted by all WTO members in 1994. Continue reading

Posted in IPR, TRIPS, TRIPS plus, Uncategorized | Leave a comment

RCEP: India in a Catch-22

By Chaitanya Netkalappa, Deccan Herald

The Regional Comprehensive Economic Partnership (RCEP) is a proposed Free Trade Agreement between the Asean countries and six other member countries that aims to boost goods and services trade by eliminating most tariff and non-tariff barriers – a move that, in theory, would provide India’s consumers greater choice of quality products at affordable rates as well as boost service (and goods) exports from the nation’s producers. Continue reading

Posted in IPR, Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment

Humira’s Best-Selling Drug Formula: Start at a High Price. Go Higher.

Humira is the best-selling prescription drug in the world. You may have seen the commercials.

Because of Humira, a woman with rheumatoid arthritis can wash her puppy in the bathtub, another with colitis can stroll happily through a fair packed with food vendors, while a third suffering from psoriasis can go to the gym without hiding her neck.

But they probably wouldn’t all look so relieved if they saw the bill. The price of Humira, an anti-inflammatory drug dispensed in an injectable pen, has risen from about $19,000 a year in 2012, to more than $38,000 today, per patient, after rebates, according to SSR Health, a research firm. That’s an increase of 100 percent. Continue reading

Posted in Biologics/Biosimilars, Drug prices, Uncategorized | Leave a comment

Cancer Drug Price Rises 1, 400% With No Generic to Challenge It

By Peter Loftus, Wall Street Journal

Since 2013, the price of a 40-year-old, off-patent cancer drug in the U.S. has risen 1,400%, putting the life-extending medicine out of reach for some patients.

Introduced in 1976 to treat brain tumors and Hodgkin lymphoma, lomustine has no generic competition, giving seller NextSource Biotechnology LLC significant pricing power.

The U.S. Food and Drug Administration is seeking to encourage more competition for drugs like lomustine, one of at least 319 drugs for which U.S. patents have expired but which have no generic copies, according to a list the agency published earlier this month. Continue reading

Posted in Cancer, Drug prices, Generics, Price hikes, Uncategorized | Leave a comment

UACT statement regarding Chilean Congress resolution calling on the President to advance the compulsory licensing request on HCV drugs

January 8, 2018 New Delhi

Source: U Act

UACT applauds the Chilean Congress resolution calling on the President to advance the compulsory licensing request on HCV drugs made in March 2017 by patients, advocates including Innovarte NGO, and elected officials. The resolution, Number 1014, passed by a 96-0 vote with one abstention, and includes the signatures of representatives across the entire political spectrum 1.

In Chile, the private market price of sofosbuvir at the time of the compulsory licensing request was approximately $36,000 USD per patient. This price is well in excess of Chile’s GNI per capita of $14,100 USD 2. The Ministry of Health currently pays $7,000 USD for a three-month supply of sofosbuvir, but is unable to treat many of the thousands of patients that require treatment, thus forcing patients to either pay exorbitant and often unaffordable prices or go untreated.

Continue reading

Posted in Compulsory Licensing, Hepatitis C | Leave a comment

Justice Prabha Sridevan on Life, Laughter and IP

By Shamnad Basheer, Spicy IP | January 4, 2018

photoAs promised in our new year post on the relativity of “newness” (and the impending death of the patent system), we bring to you our freshly minted SpicyIP Interview series. And who better to kick this off than the inimitable Justice Prabha Sridevan.

She hardly needs an introduction, as her legacy is stamped indelibly on many a fine Indian IP decision (which she penned both as high court judge and later, as the Chairman of the Intellectual Property Appellate Tribunal[IPAB]).  Continue reading

Posted in Compulsory Licensing, Patent, Uncategorized | Leave a comment